This is a working overview of tuftsin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-11 and is reviewed periodically as new material appears.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue with a C-terminal Pro-Gly-Pro tail |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Abbreviated TKPRPGP in most catalogues |
| Molecular mass | About 752 Da | Value for the free peptide |
| Solubility | Freely soluble in water | Aqueous solutions are kept cold and used promptly |
| Typical storage | -20 °C, dry, protected from light | Applies to the lyophilised powder before reconstitution |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
=== Synthesis of N-acetyl glucosamine === The path forward from fructose-6-P utilizes glmS (amidotransferase) to form glucosamine-6-P. Then, glmM (Mutase) reacts with this product to form glucosamine-1-P. hasD (acetyltransferase) converts this into n-acetylglucosamine-1-P, and finally, hasD (pyrophosphorylase) converts this product into UDP-n-acetylglucosamine.
=== Breast cancer === Docetaxel and paclitaxel have comparable efficacy metastatic breast cancer but paclitaxel has less severe side effects. Additionally, it has been noted that docetaxel is prone to cellular drug resistance via a variety of different mechanisms.
(1974), president of the University of the District of Columbia and former president of Southern University Reynold Verret (1976), president of Xavier University of Louisiana Gregory F. Ball (1977), psychologist, dean of the University of Maryland College of Behavioral and Social Sciences Thomas Worcester (1977), Jesuit academic, president of Regis College, Toronto, professor of the University of Toronto Alan Kadish (1977), president of the Touro College and University System Ralph Keen (1979), professor and dean of the honors college at the University of Illinois at Chicago Colin Crawford (1980), 24th dean of the University of Louisville School of Law and incoming dean of the Golden Gate University School of Law Samuel Hoi (1980), president of the Maryland Institute College of Art Daniel Gordis (1981), vice president of Shalem College, Israel's first liberal arts college Mark C. Gordon (1981), first president and dean of the Mitchell Hamline School of Law, former president of Defiance College and dean of the University of Detroit Mercy School of Law Donald S. Siegel (1981), economist and director of the School of Public Affairs at Arizona State University Deborah Waxman (1989), president of Reconstructionist Rabbinical College and Jewish Reconstructionist Communities Jonathan H.
Therapeutic touch has been implicated as a complementary therapy in wound healing; however, there is no high quality research supporting its use as an evidence based clinical intervention. More than 400 species of plants are identified as potentially useful for wound healing. Only three randomized controlled trials, however, have been done for the treatment of burns.
Sources: en.wikipedia.org
=== Thermoregulatory sweat test === The thermoregulatory sweat test (TST) was developed in the 1940s by Ludwig Guttmann to measure both preganglionic and postganglionic sudomotor function objectively. The test is performed in a standardized room with the temperature preheated to 45–50 °C and humidity set to 35–40%. The patient lies unclothed on an examination table. An indicator dye is evenly applied to the ventral surface of the patient's skin excluding the eyes, ears, and perioral region. The dye changes color in response to a decrease in skin pH which occurs upon the onset of sweating as the room temperature is gradually raised. Pictures are taken to record the patient's sweating patterns. In addition, a TST% is calculated by dividing the anhidrotic skin area by the total skin area and multiplying by 100. The TST% acts as an indicator of the severity of neurologic impairment. When used in conjunction with postganglionic sudomotor function testing, such as the quantitative sudomotor axon reflex test (QSART), it can differentiate a preganglionic lesion from a postganglionic lesion. A distal anhidrotic pattern is characteristic of length-dependent small fiber neuropathies, such as the distal symmetric polyneuropathy commonly seen in diabetic patients. The TST has proven to be a sensitive measure of sudomotor function. However, it is time-consuming and requires a highly specialized facility with trained personnel.
== Education and career == Okamoto received his B.S. (1964), M.S. (1966), and Ph.D. (1969) degrees from Osaka University, and served as assistant professor and associate professor at the university from 1969 to 1990. In 1990 he became a professor at Nagoya University. After retiring in 2004, he was appointed Guest Professor of EcoTopia Science Institute, Nagoya University. He was appointed as Chair Professor of Harbin Engineering University in 2007.
=== Treatment === Regulation of glyceroneogenesis is a therapeutic target of type 2 diabetes treatment, specifically inhibiting it in the liver and increasing it in adipose tissues. Insulin down-regulates glyceroneogenesis in the liver, but it also suppresses it in adipose tissue. To restrict the release of free fatty acids from adipose tissues, glyceroneogenesis must be increased so they are re-esterified. Thiazolidinedione is a substance that only affects glyceroneogenesis in adipose tissue by increasing transcription of PEPC-K to up-regulate glyceroneogenesis.
Sources: en.wikipedia.org
During the mid-1870s, a series of violent rebellions against Ottoman rule broke out in the Balkans, and the Turks responded with equally violent and oppressive reprisals. Tsar Alexander II of Russia, wanting to intervene against the Ottomans, sought and obtained an agreement with Austria-Hungary. In the Budapest Convention of 1877, the two powers agreed that Russia would annex southern Bessarabia, and Austria-Hungary would observe a benevolent neutrality toward Russia in the pending war with the Turks. As compensation for this support, Russia agreed to Austria-Hungary's annexation of Bosnia-Herzegovina. A scant 15 months later, the Russians imposed on the Ottomans the Treaty of San Stefano, which reneged on the Budapest accord and declared that Bosnia-Herzegovina would be jointly occupied by Russian and Austrian troops. The treaty was overturned by the 1878 Treaty of Berlin, which allowed sole Austrian occupation of Bosnia-Herzegovina but did not specify a final disposition of the provinces. That omission was addressed in the Three Emperors' League agreement of 1881, when both Germany and Russia endorsed Austria-Hungary's right to annex Bosnia-Herzegovina. However, by 1897, under a new tsar, the Russian Imperial government had again withdrawn its support for Austrian annexation of Bosnia-Herzegovina. The Russian foreign minister, Count Mikhail Muravyov, stated that an Austrian annexation of Bosnia-Herzegovina would raise "an extensive question requiring special scrutiny".
This mutation accelerates Aβ oligomerization, but the proteins do not form the amyloid fibrils that aggregate into amyloid plaques, suggesting that Aβ oligomerization rather than the fibrils may be the cause of this disease. Mice expressing this mutation have all the usual pathologies of Alzheimer's disease.
"You Hurled Me Into the Depths, Into the Very Heart of the Seas" is the second episode of the fourth season of the American dark comedy crime television series The Righteous Gemstones. It is the 29th overall episode of the series and was written by executive producer John Carcieri, executive producer Jeff Fradley, and series creator Danny McBride, and directed by executive producer Jody Hill. It was released on HBO on March 16, 2025, and also was available on Max on the same date. The series follows a family of televangelists and megachurch pastors led by widowed patriarch Eli Gemstone. The main focus is Eli and his immature children, Jesse, Kelvin and Judy, all of whom face challenges in their lives. The series depicts the family's past and scandals, which unleash consequences. In the episode, the Gemstones try to locate a missing Elijah for a telethon. According to Nielsen Media Research, the episode was seen by an estimated 0.264 million household viewers and gained a 0.05 ratings share among adults aged 18–49. The episode received mostly positive reviews from critics, who praised its humor, performances and character development.
Sources: en.wikipedia.org
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.
Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.
It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.